Lilly Makes Part D Pay
This article was originally published in RPM Report
Executive Summary
Lilly is quietly acknowledging that there will be a pay off from the launch of the new Medicare prescription drug benefit, thanks to the shift of many Zyprexa patients away from the price controlled Medicaid market.